Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...
The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...
Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...
Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...
New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...
The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...
After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...
The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster ...
The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...
The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price ...
The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug ...
The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback